MetaCap

XORTX Therapeutics Inc. (XRTX)

NASDAQ: XRTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.839-0.051 (-5.73%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

XRTX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.09
52-week range
0.81 – 3.60
Day range
0.8101 – 0.878
Volume / Avg
47.88K / 776.48K
Beta
—

52-week range

$0.81$3.60

XRTX stock today

Shares of XORTX Therapeutics (XRTX) finished lower on Nov 20 at $0.839, a drop of 5.73% or $0.051 per share, versus the S&P 500's 3.70% decline. Trading was light, with 47.88K shares changing hands, about 6% of the average daily volume. At this level, XRTX sits near the bottom of its 52-week range of $0.81 to $3.60: 76.7% below the high and 3.6% above the low.

XORTX Therapeutics has posted a net loss over the last twelve months (EPS of -$2.09), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About XORTX Therapeutics

Company profile

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Allen Warren Davidoff Ph.D.
Headquarters
Calgary, AB
Website
xortx.com

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.65 vs —

XRTX news

All XRTX news

XORTX Therapeutics peers

Health Care sector
XRTX peer companies
CompanyPrice% ChgMarket capCompare
EOCNEocene Ltd.1.78+1.73%$1.90Mvs XRTX
PPCBPropanc Biopharma Inc.1.78+3.19%$1.87Mvs XRTX
PPBTPurple Biotech Ltd. ADR1.53-4.09%$1.86Mvs XRTX
SBFMSunshine Biopharma Inc.2.23-5.11%$1.84Mvs XRTX
GNPXGenprex Inc.1.45-13.17%$1.94Mvs XRTX
DCOYDecoy Therapeutics Inc.0.8294-4.68%$1.98Mvs XRTX
REVBRevelation Biosciences Inc.3.50-5.15%$1.99Mvs XRTX
ENLVEnlivex Ltd.1.05-11.76%$2.01Mvs XRTX

Indexes, lists and sector

XORTX Therapeutics stock FAQ

What is XORTX Therapeutics's stock price today?

XRTX last traded at $0.839 as of Nov 20, 4:00 PM EST, down 5.73% on the day. Prices are delayed at least 15 minutes.

Who is XORTX Therapeutics's CEO?

Dr. Allen Warren Davidoff Ph.D. is the chief executive officer of XORTX Therapeutics Inc..

What is the XRTX 52-week high?

The 52-week high for XRTX is $3.60 and the 52-week low is $0.81. The stock is currently 76.7% below its high.

Compare XRTX